Aptamer Group Limited – Trademark Portfolio
Entity Type: 99
Aptamer Group Limited holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 3 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 4 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include OPTIMER and APTAMER GROUP.
Second Floor, Bio Centre,
Innovation Way, Heslington YORK YO10 5NY
Showing of trademarks Trademarks
Trademark Classifications
Aptamer Group Limited's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does Aptamer Group Limited have?
Aptamer Group Limited has 3 U.S. trademarks filed with the USPTO. Of these, 2 registered, 1 cancelled.
What trademark classes does Aptamer Group Limited file in?
Aptamer Group Limited files trademarks across 4 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 10 (Medical Apparatus), Class 44 (Medical Services). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Aptamer Group Limited's most well-known trademarks?
Aptamer Group Limited's registered trademark portfolio includes well-known marks such as OPTIMER and APTAMER GROUP. These are among 2 currently registered trademarks in the portfolio.
What is Aptamer Group Limited's trademark registration success rate?
Aptamer Group Limited has a 67% trademark registration rate, with 2 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.